Women’s health startup SheMed has raised €43 million to scale its personalised healthcare platform across the UK, deepen its clinical capabilities, and invest in next-generation data infrastructure for predictive and preventative care.
The London-based company, founded by sisters Olivia and Chloe Ferro, is on a mission to close the gender gap in medical care by delivering personalised, data-driven treatment plans that address the biological and hormonal nuances often overlooked in traditional healthcare.
The round will fund team expansion, strengthen clinical operations, and accelerate research in women’s metabolic and hormonal health, positioning SheMed as a rising force in the UK’s fast-growing HealthTech sector.
“For over a decade, I searched for answers to an undiagnosed health issue,” shared Olivia Ferro, Co-founder and CEO. “As a GLP-1 patient myself, I know how life-changing the right diagnosis and treatment can be. We built SheMed to deliver the care I couldn’t find — one that listens, understands, and empowers women.”
A Data-Driven Shift in Women’s Health
SheMed’s model blends clinical expertise, continuous wellness tracking, and personalised insights, offering women test-to-treat pathways that span diagnostics, prescriptions, and real-time health monitoring.
The company’s most popular programme — a GLP-1–based metabolic and weight management plan — has seen extraordinary adoption, serving over 60,000 women since launch. It combines medical oversight with data-led support to improve long-term health outcomes.
Later this month, SheMed will publish findings from the UK’s first female-focused GLP-1 clinical study, exploring hormonal and metabolic responses unique to women — a data milestone that could inform the next generation of female health treatments.
“Women want care that recognises their biology, their individuality, and their lived experiences,” said Chloe Ferro, Co-founder and President. “That’s why women keep turning to SheMed — for healthcare that’s not only personalised but deeply human.”
Advertisement
Riding the HealthTech Wave
SheMed’s raise comes amid a broader surge in UK and European HealthTech investment. In 2025, the UK has already seen over €14.7 billion in startup funding, with women’s health emerging as a key growth vertical.
Recent major rounds include Numan (€51.6M) for female-focused digital care and Hormona (€7.8M) for AI-driven hormone tracking — part of a broader shift toward preventative, personalised, and data-led healthcare.
Against this backdrop, SheMed’s €43M raise stands out as a signal of investor confidence in women’s health innovation — and in the Ferros’ mission to rebuild the healthcare experience around women’s needs.
The Road Ahead
Founded in April 2024, SheMed plans to use the new capital to expand nationwide, enhance its AI-driven clinical platform, and continue building partnerships with research institutions and NHS-aligned organisations.
The company is also scaling its in-house medical and engineering teams to deliver faster, more predictive care pathways — aiming to reach 250,000 women by 2026.
“This isn’t just about access,” Olivia said. “It’s about rewriting how women experience healthcare — from reactive and generic, to proactive and truly personal.”
About SheMed
SheMed is a London-based HealthTech company transforming women’s healthcare through personalised, data-driven care pathways. Founded by sisters Olivia and Chloe Ferro, the platform integrates diagnostics, treatment, and continuous support across hormonal, metabolic, and general health. With over 60,000 members and a growing research arm, SheMed is pioneering the future of women’s health — one that listens, learns, and empowers.
